The company itself is the constraint: demand outrunning its own ability to take it on, and management is spending to rai
The model's full reasoning — Q4 2022 call → NOWe need to determine if management conveys that the company's own capability is the binding limit on growth, and that they are actively spending/building/hiring NOW to raise that limit, treating it as the central task. Let's review the transcript for relevant statements. Chad Robins: "We're off to a great start in 2023. The momentum is building. We're growing revenue, advancing our pipeline, and we're managing our operating expenses. And importantly, we have the capital to fuel sustainable growth and execute on our long-range plan." He mentions managing OpEx, but not specifically about capacity being the limit. Nitin Sood on MRD: "our current penetration is about 5%. So there's a lot of room for us to grow." That suggests demand is not the issue, but they are not saying they are capacity-constrained. They are saying they have room to grow. Chad Robins: "We're off to a running start. And I'm confident in our ability to accelerate clonoSEQ penetration in our MRD business and to demonstrate our drug discovery capabilities in immune medicine." No mention of capacity being the limit. Tycho Peterson on OpEx: "we expect 2023 OpEx including cost of revenue to be slightly below our 2022 OpEx of 385.5 million. This reflects our ongoing efforts to drive operating efficiencies, while investing behind the projects to support our growth profile with higher returns." That suggests they are investing but also cutting costs. Not a race to expand capacity. Nitin Sood: "we've seen, our orders per account and institutional accounts increase by 30%. Our community business has grown from 8% of our total business to 15%. And I expect that to be 20% of our 2023 business, and all leading indicators are looking favorable new HCPs accounts grew by 50%, unique patients tested grew by 60%..." This is about growth, but not about capacity being the limit. Chad Robins: "I think I'm seeing, and I don't know, we can agree on this, but MRD in general is becoming a much more accepted by healthcare providers. It took a long time to get here. And I actually think even a lot of the noise around MRD and solid tumors, and just kind of a nomenclature and understanding kind of what the assay is, and no one wants to be first, but no one else wants to be last.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| BRBR | BellRing Brands, Inc. | Q4 2023 | 2023-11-21 | B+ |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| TSSI | TSS, Inc. | Q4 2022 | 2023-04-03 | D |
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| CHE | Chemed Corporation | Q3 2022 | 2022-11-01 | B+ |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| JBHT | J.B. Hunt Transport Services, Inc. | Q2 2022 | 2022-07-19 | C+ |
| OGI | OrganiGram Holdings Inc. | Q3 2022 | 2022-07-14 | B+ |
| FLUX | Flux Power Holdings, Inc. | Q2 2022 | 2022-02-10 | D |
| GTES | Gates Industrial Corporation plc | Q4 2021 | 2022-02-07 | C+ |
| FORM | FormFactor, Inc. | Q4 2021 | 2022-02-02 | B |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| HNRG | Hallador Energy Company | Q3 2021 | 2021-11-09 | C+ |
| FSS | Federal Signal Corporation | Q1 2018 | 2018-05-12 | A |
| AOSL | Alpha and Omega Semiconductor Limited | Q2 2018 | 2018-02-07 | B |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
| ZBH | Zimmer Biomet Holdings, Inc. | Q2 2017 | 2017-07-30 | F |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
ZBH · Q2 2017 → YESThe question is whether management conveys that the company's own ability to serve, supply, or take on business is the binding limit, and they're actively spending/building/hiring now to raise that li...YES The transcript shows management framing the Warsaw North Campus production delays and resulting back orders as the direct constraint on meeting existing customer demand and recapturing lost business, with steady market demand present but supply gating growth. They describe actively investing now in manufacturing remediation, quality enhancements, safety stock building, and sales force incentives and hires to restore full supply and return to offense, treating these as the central priority to expand capability and capture opportunities. This matches the criteria of internal capability as the binding limit and immediate action to raise it. The remediation is presented as urgent and ongoing rather than routine catch-up. The answer is YES.
FORM · Q4 2021 → YESThe question is whether management conveys that their own ability to serve/supply is the binding limit, and they're actively expanding now. YES The transcript shows management explicitly framing the company's internal limits—labor shortages in U.S. factories and extended lead times from sub-component delays—as the immediate ceiling on revenue growth, while simultaneously describing active, ongoing capital investments, facility expansions (Livermore), tool and labor additions, and supplier qualification efforts as the central priority to raise that ceiling and meet surging customer demand. This dual situation is presented as a present-tense reality driving the $850 million target path. The supply-chain component is acknowledged but subordinated to the claim that demand is outrunning current capability, and the build-out is treated as the key task ahead rather than routine maintenance.
FLUX · Q2 2022 → YESThe question is: Does management convey that the company's own ability to serve, supply, or take on business has become the binding limit on how big it can be right now — that real demand is pressing ...YES The transcript shows management explicitly framing the company's production capacity as the current binding limit: "We can’t build packs fast enough to keep up with the demand" and noting that supply-chain constraints (especially electronic components) are preventing them from serving the robust order flow and record backlog.